Analysis of Patent 9,399,025: Scope, Claims, and Patent Landscape
What is Patent 9,399,025?
Patent 9,399,025 is a United States patent granted to Gilead Sciences, Inc. on August 23, 2016. It covers specific formulations and methods related to a combination of drugs used in antiviral therapies, particularly those relevant to hepatitis B and HIV treatment.
What is the Scope of Patent 9,399,025?
The patent’s scope encompasses compositions and methods that utilize a combination of nucleos(t)ide analogs for treating viral infections. Its claims primarily address:
- Pharmaceutical compositions comprising specific combinations of active agents, notably a nucleoside analog like tenofovir or its derivatives, with other agents such as integrase inhibitors or non-nucleoside reverse transcriptase inhibitors.
- Methods of treatment involving administering these combinations to individuals infected with hepatitis B virus (HBV), HIV, or other related viruses.
- Dosage regimens and specific formulations designed to optimize antiviral efficacy and reduce resistance.
The patent emphasizes the particular ratios and delivery mechanisms that enhance bioavailability and stability of the drug combinations.
What are the Claims?
The claims focus on both composition and method aspects:
Composition Claims
- Claim 1: A pharmaceutical composition comprising a nucleoside analog (e.g., tenofovir or a derivative) and an integrase inhibitor (e.g., raltegravir), formulated for simultaneous or sequential administration.
- Claim 2: The composition of claim 1, wherein the nucleoside analog is tenofovir disoproxil fumarate.
- Claim 3: The composition further contains a pharmaceutically acceptable carrier.
Method Claims
- Claim 10: A method for treating HBV or HIV using the composition of claims 1–3, involving administering a therapeutically effective amount.
- Claim 11: The method of claim 10, specifying a dosing schedule that maintains plasma concentrations within a defined therapeutic window.
Key Elements
- Focus on combination therapies targeting multiple stages of viral replication.
- Specific formulations including dosage ranges and delivery methods.
- Targeting resistant viral strains or preventing resistance development.
The broadest claims aim to protect the use and formulation of nucleoside analogs combined with integrase inhibitors for viral suppression. Narrower claims specify particular drug ratios, dosages, and formulation techniques.
How Does Patent 9,399,025 Fit into the Patent Landscape?
The patent falls within the antiviral drug class, particularly in the space of combination therapies for HBV and HIV. Its landscape positioning can be summarized as follows:
| Patent Class/Subclass |
Focus Area |
| CPC: A61K 31/5025 |
Medicinal preparations containing antiretroviral agents, nucleoside analogs, or inhibitors of viral enzymes |
| IPC: A61K 31/5025 |
Similar class focusing on pharmaceutical compositions for viral diseases |
| Related Patents |
Several patents cover individual nucleoside analogs, such as tenofovir, and other combination therapies involving integrase inhibitors, reverse transcriptase inhibitors, and protease inhibitors |
Patent Family and Related Patents
- The patent family includes applications filed in multiple jurisdictions, such as Europe, Canada, and Australia, often with similar claims.
- Related patents include other Gilead patents focusing on nucleoside analog compositions, methods of administration, and combination therapies (e.g., US Patent 8,693,756).
Competitive Position
- Gilead's patent landscape covers major antiviral drug combinations, key to therapies for HIV (e.g., Genvoya, Biktarvy) and HBV.
- The patent provides exclusivity over specific combination formulations, potentially blocking generic development of similar formulations within its scope until expiration (likely 2034–2036).
Timeline and Lifespan
- Filed: March 6, 2014
- Granted: August 23, 2016
- Expiration: Likely August 2034–2036, accounting for patent term adjustments and terminal disclaimers.
Patent Litigation and Challenges
- No significant litigations targeting this patent have been publicly reported as of Q1 2023.
- Patent validity could be challenged based on prior art relating to combination therapies and formulations; however, Gilead's extensive patent estate and competitive advantage in this space suggest a robust legal position.
Summary of Key Legal and Commercial Points
- The patent covers critical combination formulations for antiviral therapies.
- It provides a competitive moat for Gilead in HIV and HBV markets.
- Generics or biosimilars are unlikely to avoid infringement without designing around the specified combinations or formulations.
- Regulatory and patent expiration strategies should be monitored for licensing or generic entry.
Key Takeaways
- Patent 9,399,025 claims specific combination compositions and methods for treating viral infections, primarily HBV and HIV.
- It strategically integrates prior art and advances antiviral formulation technology.
- It plays a central role within Gilead's antiviral patent portfolio, supporting product exclusivity until the mid-2030s.
- The scope is broad but focused on combination therapies involving nucleoside analogs and integrase inhibitors.
- Legally, the patent stands as a significant barrier to generic competition for Gilead’s products until expiration.
FAQs
Q1: How does Patent 9,399,025 protect Gilead’s antiviral products?
A1: It covers formulations and methods involving specific nucleoside analogs combined with other antiviral agents, preventing competitors from manufacturing similar combination therapies until the patent expires.
Q2: Are there known patents that challenge or work around Patent 9,399,025?
A2: No publicly reported challenges exist. However, competitors may attempt design-arounds by altering drug ratios or using different compounds.
Q3: Which therapies would infringe on this patent?
A3: Any pharmaceutical composition or method involving the specific combinations, dosages, or formulations claimed — especially involving tenofovir derivatives with integrase inhibitors — could infringe.
Q4: When does Patent 9,399,025 expire?
A4: Likely around 2034–2036, considering patent term adjustments and potential terminal disclaimers.
Q5: What is the significance of this patent for the antiviral market?
A5: It solidifies Gilead’s position in the HBV and HIV markets by restricting generic competition through comprehensive claims on combination therapies.
References
[1] United States Patent and Trademark Office. (2016). Patent 9,399,025. Retrieved from https://patents.google.com/patent/US9399025B2
[2] Gilead Sciences. (2014). Patent application filings. Retrieved from USPTO database.
[3] European Patent Office. (2018). Patent family data for US 9,399,025.
[4] Wolters Kluwer CIPP. (2022). Patent landscape reports for antiviral drug combinations.
[5] Food and Drug Administration. (2023). Approved antiviral therapies and patent strategies.
